Omeros (NASDAQ:OMER) Upgraded by RODMAN&RENSHAW to Strong-Buy Rating

RODMAN&RENSHAW upgraded shares of Omeros (NASDAQ:OMER) to a strong-buy rating in a research note published on Thursday morning,Zacks.com reports.

Other equities research analysts have also issued reports about the company. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Thursday. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a report on Thursday. StockNews.com lowered shares of Omeros from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Finally, Rodman & Renshaw initiated coverage on shares of Omeros in a research note on Thursday. They set a “buy” rating and a $9.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $9.00.

Omeros Trading Down 2.9 %

Omeros stock opened at $6.75 on Thursday. The firm has a market cap of $391.16 million, a P/E ratio of -2.92 and a beta of 1.47. Omeros has a 1-year low of $1.38 and a 1-year high of $7.51. The firm has a 50-day moving average of $4.14 and a 200-day moving average of $4.11.

Institutional Investors Weigh In On Omeros

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its holdings in shares of Omeros by 75.5% during the 1st quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 12,951 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Omeros in the 1st quarter worth about $85,000. Comerica Bank lifted its position in Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 5,000 shares during the period. Vanguard Group Inc. boosted its stake in Omeros by 2.6% during the first quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock worth $11,213,000 after acquiring an additional 81,348 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Omeros by 16.6% in the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after purchasing an additional 31,081 shares during the period. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.